Swiss Rockets secured an exclusive license to MGI/Complete Genomics’ CoolMPS sequencing chemistry for regions outside Asia‑Pacific and plans to launch CoolMPS‑based next‑generation sequencers as soon as next year. The Basel‑based holding company said the license supports its precision‑medicine strategy and positions it to commercialize CoolMPS in Europe and the U.S. Swiss Rockets will rely on Complete Genomics and MGI for R&D and manufacturing support while asserting that a Swiss entity may be better positioned geopolitically to market the technology in Western markets. The deal includes an option to expand rights to Asia‑Pacific in 2026, subject to MGI’s decisions. The move injects a new competitor into the NGS instrument market and signals continued fragmentation and territorial licensing of sequencing chemistries amid geopolitical and commercial tensions.